The von Hippel-Lindau tumor suppressor pVHL regulates the stability of hypoxia-inducible factors (HIF)-1 and -2, oxygen-sensitive basic helix-loop-helix transcription factors, which mediate the hypoxic induction of angiogenic growth factors such as vascular endothelial growth factor. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2 and is associated with the development of highly vascularized tumors in multiple organs. We have used a conditional gene-targeting approach to investigate the relative contributions of HIF-1 and HIF-2 to VHL-associated vascular tumorigenesis in a mouse model of liver hemangiomas. Here we demonstrate genetically that conditional inactivation of HIF-2a suppressed the development of VHL-associated liver hemangiomas and that angiogenic gene expression in hepatocytes is predominantly regulated by HIF-2 and not by HIF-1. These findings suggest that HIF-2 is the dominant HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-2 may be an effective strategy for their treatment.
The von Hippel-Lindau tumor suppressor pVHL regulates the stability of hypoxia-inducible factors (HIF)-1 and -2, oxygen-sensitive basic helix-loop-helix transcription factors, which mediate the hypoxic induction of angiogenic growth factors such as vascular endothelial growth factor. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2 and is associated with the development of highly vascularized tumors in multiple organs. We have used a conditional gene-targeting approach to investigate the relative contributions of HIF-1 and HIF-2 to VHL-associated vascular tumorigenesis in a mouse model of liver hemangiomas. Here we demonstrate genetically that conditional inactivation of HIF-2a suppressed the development of VHL-associated liver hemangiomas and that angiogenic gene expression in hepatocytes is predominantly regulated by HIF-2 and not by HIF-1. These findings suggest that HIF-2 is the dominant HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-2 may be an effective strategy for their treatment. Oncogene (2008) 27, 5354-5358; doi:10.1038 /onc.2008 published online 19 May 2008 Keywords: von Hippel-Lindau (VHL) tumor suppressor; hypoxia-inducible factor (HIF); hemangioma; liver angiogenesis; mouse model; Cre-loxP recombination Patients with germ-line mutations in the von HippelLindau (VHL) tumor suppressor, pVHL, develop a familial tumor syndrome characterized by the development of highly vascularized tumors. The most common clinical manifestation of VHL disease are hemangioblastomas, which typically develop in the central nervous system (CNS) and retina, and can also manifest in other organs such as the liver (McGrath et al., 1992; Maher and Kaelin, 1997) . Although not malignant, hemangioblastomas are clinically devastating vascular tumors and consist of pericytes, endothelial, stromal and mast cells. They are thought to originate from pVHL-deficient stromal cells, which express high levels of vascular endothelial growth factor (VEGF) and the transcription factor hypoxia-inducible factor (HIF)-2a (Vortmeyer et al., 1997; Flamme et al., 1998) resulting in the proliferation of neighboring endothelial cells. pVHL is the substrate recognition component of an E3-ubiquitin ligase, which targets the oxygen-sensitive a-subunit of HIF for ubiquitination and proteasomal degradation under normoxia and thus plays a critical role in the regulation of molecular oxygen sensing. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2, whose individual contributions to VHL-associated tumorigenesis are currently under investigation (Kapitsinou and Haase, 2008) .
VHL-associated vascular tumorigenesis can be modeled in mice by conditional inactivation of Vhlh (murine VHL) in hepatocytes, resulting in constitutive activation of Hif-1 and Hif-2, and the development of cavernous liver hemangiomas (Haase et al., 2001; Rankin et al., 2005) . Although VHL-associated liver hemangiomas and CNS hemangioblastomas are distinct with regard to their cellular origin, they share common histological features, such as endothelial cell proliferation, angiectasis and lipid droplet accumulation in neoplastic cells (Haase et al., 2001) . We have used this mouse model as a genetic tool to dissect the relative contributions of individual HIF transcription factors to VHL-associated vascular tumor development. We have previously shown that liver hemangioma formation does not require HIF-1a, but is dependent on the HIF-b subunit, also known as arylhydrocarbon receptor nuclear translocator (ARNT), suggesting that HIF-2a may play an essential role in VHL-associated vascular tumorigenesis (Rankin et al., 2005) .
To investigate the role of HIF-2 in this process, we have used Cre-loxP recombination-based gene targeting to inactivate Hif-2a in Vhlh-deficient mice that are prone to the development of cavernous liver hemangiomas (Rankin et al., 2005) . In this model, Vhlh is targeted in approximately 20-30% of hepatocytes by Cre recombinase under control of the phosphoenolpyruvate carboxykinase (PEPCK) promoter (Rankin et al., 2005) . Recombination of Vhlh and Hif-2a conditional alleles occurred with similar efficiency in PEPCK-Cre expressing mice that were homozygous for both alleles, which from hereon are referred to as PEPCK-Vhlh/Hif-2a mutants (Figure 1a) .
Cavernous hemangiomas were observed in B35% of PEPCK-Vhlh mutants 6 months of age or older (4/11), while B80% of mutants developed microscopic vascular lesions (9/11), which were characterized by angiectasis, proliferating endothelial cells and the presence of lipid droplet-containing hepatocytes (Figures 1b and c ; Rankin et al., 2005) . Similarly, 5 of 10 PEPCK-Vhlh/ Hif-1a mutant mice developed cavernous hemangiomas and 7 of 10 developed microscopic vascular lesions that were histologically identical to those in PEPCK-Vhlh mutant mice (Figures 1b and c and macroscopically similar to control mice with the exception of one case (1/13) in which a small area of angiectasis was detected by macroscopic inspection. Strikingly, cavernous hemangiomas were not observed in PEPCK-Vhlh/Hif-2a mutants at ages 8 months or older (Figure 1b) . These results indicate that Hif-2 is required for the development of VHL-associated vascular tumors in the liver. Immunohistochemical analysis of Hif-a expression revealed that both Hif-1a and Hif-2a were detectable in hepatocytes that neighbored vascular lesions, suggesting a paracrine mechanism by which an HIF-induced excessive production of hepatocyte-derived angiogenic growth factors resulted in endothelial cell proliferation and vascular tumor development (PEPCK-Cre targets hepatocytes and not endothelial cells; Figure 1d ). This is mechanistically consistent with hemangioblastoma development in the CNS, where pVHL-deficient stromal cells are the source of HIF-2-induced vascular growth factor production. Interestingly, the absence of Hif-1a did not change the histological appearance of vascular networks and lesions, nor did it affect lipid droplet accumulation in hepatocytes (Figures 1b and c) , suggesting that Hif-1 is dispensable for hemangioma development in this model. Aside from its role in the pathogenesis of VHLassociated hemangiomas and hemangioblastomas, HIF-2 expression has been associated with poor clinical outcome in a variety of other tumor types, which include renal cell and hepatocellular cancer, melanoma and neuroblastoma (Holmquist-Mengelbier et al., 2006; Rankin and Giaccia, 2008) . These observations, together with our findings suggest that pharmacological targeting of HIF-2 rather than HIF-1 may be a more effective strategy in the treatment of certain tumor types.
Since the development of VHL tumors is associated with increased angiogenic growth factor production, in particular VEGF (Flamme et al., 1998) , we examined the role of Hif-2 in the regulation of Vegf in Vhlh knockout livers. Real-time PCR analysis demonstrated that inactivation of Hif-2, but not Hif-1, was sufficient to suppress Vegf despite increased Hif-1 transcriptional activity, suggesting that Hif-2 is the dominant HIF for the regulation of hepatic Vegf (Figure 2a) . We next sought to identify and characterize additional changes in angiogenic gene expression by cDNA microarray analysis. Due to limited Cre-recombinase expression in PEPCK-Cre livers, we utilized Albumin-Cre transgenic mice to inactivate Vhlh, Hif-1a and Hif-2a in a larger percentage (>90%) of hepatocytes. Genes that were differentially expressed (>1.5-fold) between Vhlh/Hif1a/Hif-2a (mice that lack both Hif-1 and Hif-2) and Vhlh/Hif-1a or Vhlh/Hif-2a mutant livers, were sorted according to functional categories using the NIH David gene ontology program. Using this approach, we identified 17 additional HIF-regulated genes that are involved in blood vessel morphogenesis and development, angiogenesis and vasculature development, 12 of which were upregulated in Vhlh or Vhlh/Hif-1a mutant livers (Figure 2b ). Using real-time PCR analysis, we determined that inactivation of Hif-2a suppressed the majority of upregulated genes (12 of 13) more efficiently (>75% reduction) than Hif-1a inactivation, suggesting Hif-2 dominance in the transcriptional regulation of angiogenic genes (Figure 2b ). Among the genes identified was Hey1, a transcriptional target of Notch, which is involved in cardiovascular development (Figure 2c ; Fischer et al., 2004) . Recent reports demonstrated that Notch signaling is enhanced during hypoxia through functional interaction of HIF-1a with the Notch intracellular domain, providing a possible explanation for increased Notch target gene expression under conditions of HIF activation (Gustafsson et al., 2005) . Other genes induced in an Hif-2-dependent manner Mutant mice were generated in a mixed genetic background (Balb/C, 129Sv/J, C57BL/6) and littermates not carrying the Cre-transgene were used as controls. Due to mixed genetic backgrounds, two different Hif-2a wild-type alleles were detected in Vhlh mutants, representing a polymorphism in the Hif-2a allele. Note that PEPCK-Cre efficiently recombines both the Vhlh and Hif-2a conditional alleles in mice homozygous for the Vhlh and Hif-2a conditional alleles (lanes 3 and 4). Abbreviations: 2-lox, nonrecombined allele; 1-lox, recombined allele; wt, wild-type allele; T, tail; L, liver. Generation and analysis of the Vhlh, Hif-1a, Hif-2a and Arnt conditional alleles, Albumin-Cre and PEPCK-Cre transgenes was performed as described (Rankin et al., 2005 (Rankin et al., , 2007 Gruber et al., 2007) . Lower panel: Hif-2a protein levels in Vhlh mutant mice. Western blot analysis of nuclear protein extracts isolated from the livers of PEPCK-Vhlh, -Vhlh/Hif-2a and Cre-negative mice. Albumin-Vhlh and -Vhlh/Hif-2a protein extracts are shown as positive control for Hif-2a expression and to demonstrate that Hif-2a is efficiently deleted in hepatocytes (absence of Hif-2a in Vhlh/Hif-2a mutants). Please note that only up to 20-30% of hepatocytes undergo recombination in PEPCK-Cre mutants compared to>90% of hepatocytes in Albumin-Cre mutants. This results in only a minor increase in Hif-2a protein levels in PEPCK-Vhlh mutants compared to Cre-negative controls. DNA and protein extracts were prepared and analysed as previously described (Rankin et al., 2005) . Abbreviation: ns, nonspecific band. Arrows point to hepatocytes with positive nuclear staining for Hif-a subunits. Note that the pattern of Hif-1a and Hif-2a staining is similar in Vhlh-deficient livers. Nuclear Hif2a staining was also detected in clusters of nonhepatocyte cells that are associated with vascular lesions and contain Ki67-and CD34-positive cells (c). Double-headed arrows depict Hif-2a positive cells, which contain macrovesicular lipid droplets; asterisk indicates a blood filled vascular cavity (magnification, Â 400). Anti-Hif-1a and anti-Hif-2a rabbit polyclonal antiserum (Novus, Littleton, CO, USA) was used for the immunohistochemical detection of Hif-a subunits in paraffin-embedded liver sections employing a horseradish peroxidase-based high-amplification signal detection system (CSA, Dako, Carpinteria, CA, USA) with 3,3 0 -diaminobenzidine as enzymatic substrate.
included Bmp4, a TGF-b super family member previously shown to regulate tumor angiogenesis (Figure 2c ; Rothhammer et al., 2007) , Klf5, Nr2f2, Angpt13, Anxa2 and Cdh5 (Figure 2c ). Whether increased expression of these genes resulted from direct transcriptional regulation by Hif-2 or was a consequence of increased angiogenesis is unclear and requires further analysis.
The expression of other HIF-2 targets that are commonly associated with pVHL-defective tumors, such as cyclin D1 (CCND1) (White et al., 2005) . When compared to Vhlh/Hif-1a/Hif-2a mutant livers 1123 and 197 cDNAs were significantly changed in Vhlh/Hif-1a and Vhlh/Hif-2a livers respectively. Genes were grouped into functional gene ontology categories using NIH DAVID. Genes@Work (IBM) was used to generate a heat map depicting gene expression levels in Albumin-Vhlh/Hif-1a/Hif-2a (Group C, n ¼ 4), Albumin-Vhlh/Hif-1a (Group A, n ¼ 3) and Albumin-Vhlh/Hif-2a (Group B, n ¼ 4) mutant livers compared to a common reference RNA sample. Red and green boxes represent an increase and decrease in fold expression respectively. Each column represents an individual liver sample. Genes were clustered using Euclidian average linkage clustering. (c) Validation of microarray gene expression by real-time PCR analysis. Fold changes in gene expression for the indicated genotype (n ¼ 4) compared to Cre-negative littermate livers (n ¼ 4) are shown; red and green boxes indicate an increase and decrease in mRNA levels respectively. mRNA levels were normalized to 18S. NS, absence of statistically significant differences between mutant and control livers. not change in the liver (data not shown), indicating that HIF-2-mediated induction of gene expression is tissueand context dependent. Although a specific polymorphism in the CCND1 gene was found to be associated with increased susceptibility to retinal and CNS hemangioblastomas in one study (Zatyka et al., 2002) , no clear correlation between CCND1 genotype and expression was found in another clinical report (Gijtenbeek et al., 2005) .
Collectively, our findings demonstrate that HIF-2 is the dominant HIF for the regulation of VEGF and other angiogenic factors in hepatocytes. A role for HIF-2 in the regulation of VEGF has recently been observed in human renal cell cancer and neuroblastoma cell lines, while in other cell types such as thymocytes and astrocytes Vegf expression was found to be Hif-1 dependent (Biju et al., 2004; Chavez et al., 2006; Holmquist-Mengelbier et al., 2006) . Taken together these data suggest that both HIF-1 and HIF-2 have the ability to activate VEGF, however, they appear to preferentially regulate its expression within individual cell types. This may be attributable to different HIF-1 and HIF-2 expression levels in individual cell types or may be due to the presence of cell-specific transcriptional cofactors that modulate HIF activity. In the context of human VHL-associated hemangioblastomas, high levels of HIF-2 are associated with increased VEGF mRNA levels, while correlation of HIF-1 expression with tumor VEGF levels was poor (Flamme et al., 1998) , which is consistent with our data in mice.
In summary, our studies provide genetic evidence that HIF-2 is the critical regulator of angiogenic gene expression and vascular tumorigenesis in pVHL-deficient livers and may therefore represent a therapeutic target for the treatment of VHL-associated vascular tumors.
